Garman TS, Kates MR. Re: Maria De Santis, Joan Palou Redorta, Hiroyuki Nishiyama, et al. Durvalumab in Combination with BCG for BCG-naive, High-risk, Non-muscle-invasive Bladder Cancer (POTOMAC): Final Analysis of a Randomised, Open-label, Phase 3 trial. Lancet 2025;406:2 Eur Urol 2026 Jan 19:S0302-2838(26)00016-3. doi: 10.1016/j.eururo.2026.
PMID: 41558887